Our results demonstrate the utility of blocking intracellular STAT3 signaling upon targeting of the therapeutically unexplored CC domain of STAT3 and pave a way towards inhibitory strategies in diverse diseases including cancer and autoimmune disorders. The gene discussed is STAT3; the disease is cancer.